Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Balaxi Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	145.59	394	622.91	282.17	71.93
Short-Term Investments	-	19.84	13.04	2.81	2.48	1.84
Cash & Short-Term Investments	165.43	165.43	407.03	625.72	284.65	73.77
Cash Growth	-59.36%	-59.36%	-34.95%	119.82%	285.85%	342.01%
Accounts Receivable	-	1,361	1,108	557.05	522.82	275.59
Other Receivables	-	31.62	21.12	12.95	10.73	18.48
Receivables	-	1,397	1,160	589.01	550.02	311.84
Inventory	-	834.8	784.81	821.68	1,050	987.04
Prepaid Expenses	-	52.93	22.14	20.17	37.77	31.22
Other Current Assets	-	64.16	53.53	45.14	12.44	6.16
Total Current Assets	-	2,514	2,428	2,102	1,935	1,410
Property, Plant & Equipment	-	490.11	363.11	170.87	190.16	60.27
Long-Term Investments	-	-	-	-	-	44.7
Goodwill	-	326.71	267.45	261	252.24	233.02
Other Long-Term Assets	-	39.18	45.21	49.84	19.19	16.69
Total Assets	-	3,370	3,103	2,583	2,397	1,765

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	212.08	161.78	290.38	345.19	491.15
Accrued Expenses	-	54.2	46.02	46.1	28.02	32.6
Short-Term Debt	-	334.37	303.8	176.61	107.51	36.38
Current Income Taxes Payable	-	20.89	33.67	28.83	50.57	72.52
Other Current Liabilities	-	0.05	0.05	0.05	0.05	0.03
Total Current Liabilities	-	621.58	545.32	541.98	531.33	632.68
Long-Term Debt	-	223.53	212.45	-	8.7	-
Long-Term Leases	-	18.59	18.01	17.43	16.86	-
Long-Term Deferred Tax Liabilities	-	13.35	9	9.95	11.01	0.39
Other Long-Term Liabilities	-	2.49	1.29	0.43	-	-
Total Liabilities	-	879.53	786.06	569.79	567.89	633.06

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	110.42	110.42	108.98	101.81	100
Additional Paid-In Capital	-	565.8	565.8	508.44	192.46	112.53
Retained Earnings	-	1,815	1,641	1,358	1,432	919.11
Comprehensive Income & Other	-	-	-	37.73	102.97	-
Shareholders' Equity	2,491	2,491	2,317	2,014	1,829	1,132
Total Liabilities & Equity	-	3,370	3,103	2,583	2,397	1,765

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	576.49	576.49	534.25	194.04	133.07	36.38
Net Cash (Debt)	-411.06	-411.06	-127.22	431.68	151.58	37.39
Net Cash Growth	-	-	-	184.78%	305.40%	-
Net Cash Per Share	-7.58	-7.45	-2.30	8.39	2.99	0.75
Filing Date Shares Outstanding	54.06	55.21	55.21	50.91	50.91	50
Total Common Shares Outstanding	54.06	55.21	55.21	50.91	50.91	50
Working Capital	-	1,893	1,882	1,560	1,404	777.36
Book Value Per Share	45.12	45.12	41.98	39.56	35.92	22.63
Tangible Book Value	2,164	2,164	2,050	1,753	1,577	898.62
Tangible Book Value Per Share	39.20	39.20	37.13	34.43	30.97	17.97

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 6, 2026

Data Sources Report a data error